Boustead Plantations Rises Again After Takeover Report
By Ying Xian Wong
Boustead Plantations shares rose early Monday after local media reported that at least four bidders are lining up to acquire a majority stake in the Malaysian agricultural company.
Shares rose as much as 10% and were recently trading at 0.96 ringgit ($0.21), up 7.9%. Year-to-date gains stand at 49%, including a 43% gain this month alone.
The Edge Weekly reported in a publication dated Monday that Boustead Holdings is looking to dispose of its 57% stake in Boustead Plantations, with YTL Corp. Bhd., IOI Corp. Bhd., Wilmar International and Kuala Lumpur Kepong among bidders for the stake.
A spokeswoman for both Boustead Holdings and Boustead Plantations told The Wall Street Journal that she didn't have any details about plans for a stake disposal.
KLK was 5.1% higher in early trading, while the other three reported bidders were 0.5% to 1.5% lower.
Maybank Investment Bank analyst Ong Chee Ting on Monday kept a hold rating on Boustead Plantations, saying that any buyers will likely push for a discount on shares. "Potential buyer(s) is likely to require a hefty discount to factor in huge capex requirements to turn around Boustead Plantations' aging trees, as 46% of its oil palm trees are past prime (i.e. >20 yrs old)," he wrote in a research note.
The analyst advised shareholders "to hold out for a potential general offer," saying the upside is likely capped at the company's net tangible asset value of MYR1.30/share. He cautioned, however, that "failure to seal a deal may cause [the company's] share price to give back recent gains."
Maybank raised its target price on Boustead Plantations to MYR0.92 from MYR0.72.
Write to Ying Xian Wong at yingxian.wong@wsj.com
(END) Dow Jones Newswires
June 18, 2023 23:16 ET (03:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth